For millions of people living with chronic conditions like heart failure or type 2 diabetes, the hardest part of care is often just getting to the doctor. Missed appointments, long drives, crowded waiting rooms — these barriers are so routine they barely register as problems anymore. But they kill.
Patients deteriorate. Hospital readmissions spike.
The system buckles. Cadence, a company that builds remote patient monitoring technology, just raised $100 million in Series C funding to attack that problem head-on. Spark Capital led the round.
Two large health systems — Memorial Hermann and Duke Health — also put money in. That last detail is the real signal here.
Health systems do not typically invest in technology they view as a nice-to-have. They invest in what they think will work at scale. The platform covers hypertension, type 2 diabetes, heart failure and chronic obstructive pulmonary disease.
These are the four horsemen of the American healthcare crisis. Together they account for a staggering share of hospital costs, emergency visits, and early deaths. Cadence’s pitch is straightforward: let patients track their vital signs and symptoms from home, share that data with their care teams in real time, and catch problems before they become crises.
The company says it wants to use the new funding to expand its technology across more health systems and advance its AI agents. AI agents in clinical care remain an emerging technology.
That is a plain fact. Their role in actual medical decision-making is still being studied. No one should pretend otherwise.
But the logic behind them is not complicated. A human care team can only watch so many patients at once.
An AI agent can monitor thousands, flagging the one whose blood pressure is climbing or whose weight gain suggests fluid buildup. It is triage, automated. It is a safety net, not a replacement.
The stakes here are concrete. Patients who struggle with frequent clinic visits — the elderly, the rural, the working poor — stand to gain the most. Remote monitoring can keep them connected to their doctors without requiring them to show up in person.
That is not a small thing. That is the difference between catching heart failure early and ending up in the emergency room at 3 a.m. Early evidence on these platforms is still developing.
The report acknowledges that. But the involvement of Memorial Hermann and Duke Health suggests major providers see enough promise to risk capital. That matters.
It means the technology is moving out of pilot programs and into real clinical workflows. Cadence also plans to grow value-based care models.
Those are payment arrangements where providers are rewarded for keeping patients healthy, not just for performing procedures. Remote monitoring fits naturally into that framework. If a platform can help a patient manage hypertension at home, the health system saves money on hospital stays.
Everyone wins — except, perhaps, the old status quo. Patients should talk to their doctors before changing anything based on new technology. That is always the right advice.
But the direction is clear. The money is flowing.
The health systems are signing on. The question is no longer whether remote monitoring will matter. It is how fast it will spread, and who will get left behind if it does not.
